Comparison of the biocompatibility of gatifloxacin 0.3% and moxifloxacin 0.5%

Cornea

Volumn 25, Issue 9 SUPPL. 2, 2006, Pages

  Kaufman, Stephen C ^a   Rusinek, Christopher ^a   Salahuddin, Azhar ^a   Ahee, Jason ^a   Prasad, Anu ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

Biocompatibility; Fourth generation fluoroquinolones; Gatifloxacin; Moxifloxacin

Indexed keywords

GATIFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BIOCOMPATIBILITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFOCAL MICROSCOPY; CONJUNCTIVA EPITHELIUM; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA EPITHELIUM; CORNEA ULCER; CYTOTOXICITY; DOSIMETRY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG FORMULATION; EYE PAIN; EYE TOXICITY; FEMALE; HUMAN; MALE; PAIN ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUPIL; RANDOMIZED CONTROLLED TRIAL; TOXICITY TESTING; VISUAL ACUITY;

EID: 33845410098     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ico.0000214210.52694.d2     Document Type: Article

References (14)

1. Mather R, Karenchak L, Romanowski E, et al. Fourth-generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol. 2002;133:463-466.
2. Xu KP, Li XF, Yu FS. Corneal organ culture model for assessing epithelial responses to surfactants. Toxicol Sci. 2000;58:306-314.
3. Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv Ther. 2001;18:205-215.
4. Ng EW, Joo MJ, Eong KG, et al. Ocular toxicity of intravitreal trovafloxacin in the pigmented rabbit. Curr Eye Res. 2003;27:387-393.
5. Scuderi AC, Paladino GM, Marino C, et al. In vitro toxicity of netilmicin and ofloxacin on corneal epithelial cells. Cornea. 2003;22:468-472.
6. Stevens SX, Fouraker BD, Jensen JG. Intraocular safety of ciprofloxacin. Arch Ophthalmol. 1991;109:1737-1743.
7. Fish DN. Fluoroquinolone adverse effects and drug interactions. Pharmacotheraphy 21:253S-272S.
8. Donnenfeld ED, Perry HD, Chruscicki DA, et al. A comparison of the fourth-generation fluoroquinolones gatifloxacin 0.3% and moxifloxacin 0.5% in terms of ocular tolerability. Curr Med Res Opin. 2004;2:1753-1758.
9. Farley WJ, Luo L, Chen LZ, et al. Effects of commercial 4th-generation fluoroquinolones on corneal epithelial barrier function in experimental murine dry eye. Presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), April 25-29, 2004, Fort Lauderdale, FL.
10. Schmidt LP, Beuerman RW. Comparison of gatifloxacin and moxifloxacin in healing of a linear incision in the rabbit cornea. Presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), April 25-29, 2004, Fort Lauderdale, FL.
11. Gao J, Siemasko KF, Vu C, et al. Effect of the fourth-generation fluoroquinolone on rabbit corneal wound healing. Presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), April 25-29, 2004, Fort Lauderdale, FL.
12. Nguyen QH, Friedlander MH, Sharf L, et al. Objective and subjective measurements of drug toxicity. Presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), April 25-29, 2004, Fort Lauderdale, FL.
13. Sami MS, Setabutr P, Folterman MO, et al. Epithelial healing rates with topical moxifloxacin and gatifloxacin aftyer bilateral photorefractive keratectomy. Presented at the Annual Cornea Society Meeting, October 22, 2004, New Orleans, LA.
14. Solomon R, Donnenfeld ED, Perry HD, et al. The effect of gatifloxacin 0.3% and moxifloxacin 0.5% on corneal epithelial wound healing following photorefractive keratectomy. Presented at the Annual Meeting of the American Academy of Ophthalmology (AAO), October 23-26, 2004, New Orleans, LA.